Skip Navigation


Annals of Oncology Advance Access originally published online on January 30, 2008
Annals of Oncology 2008 19(3):409-410; doi:10.1093/annonc/mdn004
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
19/3/409    most recent
mdn004v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Marino, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marino, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org

editorial

Measuring the cost of chemotherapy is important, but it is not enough

P. Marino

INSERM Research Unit 912, and Institut Paoli-Calmettes, Marseilles, France

(E-mail: marino@marseille.inserm.fr)

The first 10% of the full text of this article appears below.

Most therapeutic innovations in oncology currently induce limited improvements of the expected health outcomes while they are associated with an important increase in costs and toxicity of treatments. This trend indicates that technical progress in this field follows a law of diminishing returns: increased resources have to be committed to produce one additional unit of outcome, like an additional year of survival for cancer patients. Economic assessments and cost-effectiveness considerations are consequently attracting a growing attention in public debates about adoption, diffusion and regulation of new treatments.

Cost-effectiveness analysis (CEA) and its derivative cost-utility analysis (CUA) are methods of summarizing information on the relationship between resources, measured in monetary terms, that are expended on health interventions, and the health outcomes, measured in numerical units, as a change in health or functional status that result from these interventions [1. . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?